Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LEXX

Lexaria Bioscience Corp

Jan 14 • 04:00PM ET

1.93

Dollar change -0.13
Percentage change -6.31	%

Healthcare • Biotechnology • Canada • NASD

Peers: TLRY CRON IIPR CARA CGC ACB OGI VFF APH OGEN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.49	Insider Own	7.28%	Shs Outstand	17.45M	Perf Week	-11.47%
Market Cap	33.88M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	3.99%	Shs Float	16.28M	Perf Month	-17.52%
Income	-7.32M	PEG	-	EPS next Q	-0.12	Inst Own	6.05%	Short Float	3.16%	Perf Quarter	-37.74%
Sales	0.50M	P/S	67.76	EPS this Y	11.70%	Inst Trans	4.82%	Short Ratio	3.36	Perf Half Y	-33.68%
Book/sh	0.56	P/B	3.45	EPS next Y	18.07%	ROA	-109.08%	Short Interest	0.51M	Perf Year	26.97%
Cash/sh	0.46	P/C	4.17	EPS next 5Y	-	ROE	-108.31%	52W Range	1.36 - 6.85	Perf YTD	-8.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.61%	ROI	-74.11%	52W High	-71.82%	Beta	1.09
Dividend TTM	-	Quick Ratio	29.64	Sales past 5Y	40.03%	Gross Margin	83.24%	52W Low	41.91%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	29.64	EPS Y/Y TTM	56.62%	Oper. Margin	-1448.67%	RSI (14)	36.88	Volatility	12.56% 9.67%
Employees	7	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-1473.01%	Recom	1.00	Target Price	9.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-24.48%	Payout	-	Rel Volume	15.06	Prev Close	2.06
Sales Surprise	-58.00%	EPS Surprise	-16.67%	Sales Q/Q	21.58%	Earnings	Oct 30	Avg Volume	153.29K	Price	1.93
SMA20	-11.81%	SMA50	-13.46%	SMA200	-32.39%	Trades		Volume	2,308,122	Change	-6.31%

Jan-14-25 09:10AM	Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R) (ACCESSWIRE) -6.31%
Dec-19-24 09:05AM	Lexaria's Registered GLP-1 Study #4 Begins Dosing (ACCESSWIRE)
Dec-18-24 09:25AM	Lexaria Forms New Scientific Advisory Board (ACCESSWIRE)
Dec-17-24 09:10AM	Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience (ACCESSWIRE)
Dec-10-24 09:43AM	Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide (TipRanks)
09:10AM	Loading…
Dec-09-24 09:10AM	Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 (ACCESSWIRE)
Nov-30-24 11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, and Surge Battery Metals (Newsfile)
11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals (Newsfile)
Nov-26-24 09:20AM	Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs (ACCESSWIRE)
Nov-25-24 09:00AM	Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled (ACCESSWIRE)
Nov-20-24 09:05AM	ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study (ACCESSWIRE)
Nov-14-24 09:10AM	Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study (ACCESSWIRE) -6.19%
Nov-13-24 09:20AM	Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss (ACCESSWIRE)
Nov-07-24 09:15AM	Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments (ACCESSWIRE) +5.94%
Oct-24-24 09:10AM	Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
09:20AM	Loading…
Oct-22-24 09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-16-24 04:00PM	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Oct-15-24 08:25AM	Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -6.21%
Oct-09-24 09:05AM	Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (ACCESSWIRE)
Oct-08-24 09:20AM	Lexaria Updates Current GLP-1 Market (ACCESSWIRE)
Oct-01-24 09:25AM	Lexaria Appoints Michael Shankman as Chief Financial Officer (ACCESSWIRE)
Sep-27-24 09:20AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 (ACCESSWIRE)
Sep-05-24 10:00AM	Lexaria Releases Strategic Letter from the Outgoing CEO (ACCESSWIRE)
09:00AM	Lexaria Welcomes Industry Veteran as New CEO (ACCESSWIRE)
Sep-03-24 08:30AM	Lexaria Enters a Material Transfer Agreement for DehydraTECH Research (ACCESSWIRE) -6.65%
Aug-29-24 09:25AM	Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules (ACCESSWIRE) +10.62%
Aug-27-24 09:20AM	First Results from Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Aug-22-24 09:20AM	Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE) -7.90%
Aug-21-24 09:00AM	Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Aug-19-24 09:05AM	Positive Results from Lexaria's Molecular Characterization Study (ACCESSWIRE)
10:30AM	Loading…
Jul-17-24 10:30AM	Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study (ACCESSWIRE)
Jul-16-24 09:20AM	Lexaria Preparing For Strategic Growth (ACCESSWIRE)
Jul-12-24 05:52PM	LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
Jul-09-24 09:10AM	Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jul-08-24 09:10AM	Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy (ACCESSWIRE) -5.49%
Jun-24-24 06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-18-24 09:00AM	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study (ACCESSWIRE)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.08%
Jun-05-24 09:00AM	Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-30-24 06:45AM	7 A-Rated Penny Stocks Work Betting On in H2 2024 (InvestorPlace) +5.00%
May-23-24 09:05AM	Lexaria Awards Contract For Third GLP-1 Human Pilot Study (ACCESSWIRE)
May-21-24 09:20AM	Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy (ACCESSWIRE)
May-17-24 09:10AM	Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study (ACCESSWIRE)
May-08-24 09:10AM	Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study (ACCESSWIRE)
May-06-24 09:05AM	Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs (ACCESSWIRE) +8.95%
Apr-30-24 03:40PM	Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance (ACCESSWIRE) +25.61%
Apr-16-24 09:10AM	Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study (ACCESSWIRE) +16.08%
Apr-09-24 09:52PM	LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024 (InvestorPlace) -8.78%
Apr-02-24 09:00AM	Lexaria Awarded New Patents (ACCESSWIRE)
Mar-21-24 09:20AM	Lexaria to Present at The LD Micro Invitational XIV (Newsfile) -7.03%
Mar-14-24 09:20AM	Lexaria Appoints Nelson Cabatuan as Chief Financial Officer (ACCESSWIRE) -12.50%
Mar-07-24 09:05AM	Lexaria Awards Contract For Next GLP-1 Human Pilot Study (ACCESSWIRE) +11.61%
Mar-05-24 09:05AM	Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 (ACCESSWIRE) +12.67%
Mar-04-24 09:15AM	7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study (ACCESSWIRE)
Mar-01-24 08:20AM	Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE) -15.36%
Feb-16-24 04:05PM	Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.32% +8.41%
Feb-15-24 08:00AM	Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.23%
Jan-30-24 08:45AM	Lexaria's Submits Investigational New Drug Application (ACCESSWIRE)
Jan-24-24 08:45AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-22-24 08:51AM	LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024 (InvestorPlace)
Jan-16-24 09:10AM	Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program (ACCESSWIRE)
Jan-11-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream (GlobeNewswire) +5.56%
Jan-10-24 08:30AM	GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons (PR Newswire)
Jan-09-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform (GlobeNewswire)
Jan-08-24 08:30AM	Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs (PR Newswire)
Jan-04-24 09:05AM	Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide (ACCESSWIRE) +6.92%
Dec-07-23 09:20AM	Lexaria's Investigational New Drug Application Filing Update (ACCESSWIRE)
Nov-28-23 09:10AM	Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study (ACCESSWIRE)
Nov-27-23 09:05AM	Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study (ACCESSWIRE) +24.43%
Nov-01-23 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space (GlobeNewswire) +5.07%
08:30AM	Get Ready for Next Generation of Diabetes, Weight-Management Drugs (PR Newswire)
Oct-31-23 08:31AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs (GlobeNewswire)
Oct-30-23 09:30AM	Can Diabetes, Weight-Loss Drugs Get Even Better (PR Newswire) +14.66%
Oct-13-23 09:05AM	Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn (ACCESSWIRE) -6.61%
Oct-12-23 09:10AM	Lexaria Granted Two New Patents in Canada (ACCESSWIRE)
Sep-29-23 08:00AM	Lexaria Announces Pricing of $1.6 Million Registered Direct Offering (ACCESSWIRE)
Sep-21-23 09:10AM	Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD (ACCESSWIRE)
Aug-30-23 09:20AM	Lexaria Provides Update on Investigational New Drug Application Progress (ACCESSWIRE)
Aug-28-23 09:02AM	LEXX: 3Q:23 Financial Results & Corporate Updates (Zacks)
Aug-23-23 11:12AM	Lexaria Bioscience Corp: A Comprehensive Stock Price Change Analysis (GuruFocus.com)
Aug-09-23 09:15AM	Lexaria's DehydraTECH-Nicotine Faster than ZYN and on! (ACCESSWIRE) +6.81%
Aug-02-23 09:10AM	Lexarias Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD (ACCESSWIRE)
Jul-28-23 09:10AM	Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study (ACCESSWIRE)
Jul-19-23 09:05AM	Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products (ACCESSWIRE)
Jun-26-23 07:47AM	LEXX: A Little Bit of Everything (Zacks Small Cap Research)
Jun-22-23 09:25AM	Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science (ACCESSWIRE) +8.51%
Jun-20-23 09:05AM	Lexaria Receives New Patents (ACCESSWIRE)
Jun-16-23 09:10AM	Lexarias DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study (ACCESSWIRE)
Jun-12-23 09:20AM	Lexaria Appoints New Chief Financial Officer (ACCESSWIRE)
May-23-23 09:05AM	Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers (ACCESSWIRE) +13.21%
May-18-23 04:22PM	Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH (Benzinga) +19.60% -14.94%
09:05AM	Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery (ACCESSWIRE)
May-11-23 01:45PM	Lexaria Bioscience Announces Closing of $2.0 Million Public Offering (ACCESSWIRE)
09:00AM	cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE)
May-10-23 10:15AM	Lexaria Announces 2023 Annual Meeting Results (ACCESSWIRE)
May-08-23 08:35PM	Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering (ACCESSWIRE) -21.76% -22.92%
09:05AM	Lexarias Human Clinical Nicotine Study Completes Dosing as Planned (ACCESSWIRE)
Apr-24-23 09:00AM	Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study (ACCESSWIRE)
Apr-20-23 09:00AM	Lexaria is Receiving Four New Patents (ACCESSWIRE)

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHRISTOPHER RICHARD	Chief Executive Officer	Dec 03 '24	Buy	2.47	27,172	67,175	50,000	Dec 03 02:03 PM
CHRISTOPHER RICHARD	Chief Executive Officer	Dec 02 '24	Buy	2.24	22,828	51,217	22,828	Dec 03 02:03 PM
TURKEL CATHERINE C.	Director	Aug 12 '24	Buy	3.13	1,600	5,008	3,100	Aug 13 10:55 AM
Carle Vanessa	Secretary	Jul 31 '24	Sale	4.00	2,567	10,268	0	Aug 01 12:25 PM
Carle Vanessa	Secretary	May 14 '24	Option Exercise	1.15	2,500	2,875	2,567	May 15 05:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LEXX

Lexaria Bioscience Corp

Upgrade your FINVIZ experience